Roche News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

04.06.21	Roche presents latest advances with immunotherapies in non-Hodgkin lymphoma (GlobeNewswire)
25.05.21	European Commission approves Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia who are ineligible for intensive chemotherapy (GlobeNewswire)
20.05.21	Pivotal Phase III data at ASCO show Roche’s Tecentriq helps certain people with early lung cancer live significantly longer without their disease returning (GlobeNewswire)
11.05.21	Roche to present data from one of the most comprehensive oncology portfolios at the 2021 ASCO Annual Meeting showcasing advancements for people living with cancer (GlobeNewswire)
05.05.21	Roche’s Tecentriq approved by European Commission as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer (GlobeNewswire)
28.04.21	US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche’s Tecentriq for previously untreated metastatic bladder cancer (GlobeNewswire)
28.04.21	Roche launches new ways to use their cardiovascular tests empowering clinicians to improve diagnosis and treatment of millions of people (GlobeNewswire)
28.04.21	US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche’s Tecentriq for PD-L1-positive, metastatic triple-negative breast cancer (GlobeNewswire)
23.04.21	CHMP recommends EU approval of Roche’s ENSPRYNG (satralizumab) for adults and adolescents with neuromyelitis optica spectrum disorder (NMOSD) (GlobeNewswire)
23.04.21	Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy (GlobeNewswire)
22.04.21	Roche purchases shares in tender offer for GenMark Diagnostics, Inc. (GlobeNewswire)
21.04.21	Roche mit soliden Ergebnissen im ersten Quartal 2021 (GlobeNewswire)
21.04.21	Roche reports solid results in the first quarter of 2021 (GlobeNewswire)
16.04.21	New data for Roche’s OCREVUS (ocrelizumab) reinforce significant benefit on slowing disease progression in relapsing and primary progressive multiple sclerosis (GlobeNewswire)
15.04.21	Roche’s Evrysdi continues to improve motor function and survival in babies with Type 1 Spinal Muscular Atrophy (SMA) (GlobeNewswire)
13.04.21	FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications (GlobeNewswire)
12.04.21	Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81% (GlobeNewswire)
08.04.21	New Roche data at 2021 AAN highlight impact and breadth of expanding neuroscience portfolio (GlobeNewswire)
07.04.21	Roche launches Elecsys Anti-p53 immunoassay to aid diagnosis of various cancer types (GlobeNewswire)
31.03.21	Roche launches Elecsys Epstein-Barr Virus (EBV) immunoassay panel to improve EBV infection staging (GlobeNewswire)
30.03.21	Roche’s Evrysdi approved by European Commission as first and only at home treatment for spinal muscular atrophy (GlobeNewswire)
26.03.21	Roche receives positive CHMP opinion for Tecentriq as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer (GlobeNewswire)
25.03.21	Roche commences tender offer for all shares of GenMark Diagnostics, Inc. for $24.05 per share in cash (GlobeNewswire)
23.03.21	Roche launches new high throughput configurations for cobas pro integrated solutions to increase testing efficiency (GlobeNewswire)
23.03.21	New phase III data shows investigational antibody cocktail casirivimab and imdevimab reduced hospitalisation or death by 70% in non-hospitalised patients with COVID-19 (GlobeNewswire)
22.03.21	Roche provides update on tominersen programme in manifest Huntington’s disease (GlobeNewswire)
22.03.21	Pivotal Phase III study shows Roche’s Tecentriq helped people with early lung cancer live longer without their disease returning (GlobeNewswire)
17.03.21	Roche launches cobas pure integrated solutions analyser to help simplify operations in small to medium sized labs (GlobeNewswire)
16.03.21	Roche Generalversammlung 2021 (GlobeNewswire)
16.03.21	Roche Annual General Meeting 2021 (GlobeNewswire)
16.03.21	Roche launches SARS-CoV-2 variant test to help monitor emerging coronavirus mutations (GlobeNewswire)
16.03.21	New two-year data show Roche’s Evrysdi (risdiplam) continues to demonstrate improvement or maintenance of motor function in people aged 2-25 with Type 2 or Type 3 Spinal Muscular Atrophy (SMA) (GlobeNewswire)
15.03.21	Roche signs definitive merger agreement with GenMark Diagnostics, Inc., to access novel technology to test for broad range of pathogens with one patient sample (GlobeNewswire)
11.03.21	Roche’s awarded WHO prequalification for the HIV and HCV diagnostic tests on the cobas 6800/8800 Systems (GlobeNewswire)
11.03.21	Roche provides update on the phase III REMDACTA trial of Actemra/RoActemra plus Veklury in patients with severe COVID-19 pneumonia (GlobeNewswire)
08.03.21	Roche provides update on Tecentriq US indication in prior-platinum treated metastatic bladder cancer (GlobeNewswire)
05.03.21	Roche’s Actemra/RoActemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung di (GlobeNewswire)
26.02.21	Roche SARS-CoV-2 Rapid Antigen Test receives special approval for at-home patient self-testing using nasal swabs in Germany (GlobeNewswire)
26.02.21	EMA issues advice on casirivimab and imdevimab antibody cocktail for the treatment of mild-to-moderate COVID-19 (GlobeNewswire)
26.02.21	Roche receives positive CHMP opinion for Evrysdi, the first and only at home spinal muscular atrophy (SMA) treatment with proven efficacy in adults, children and infants two months and older (GlobeNewswire)
25.02.21	Roche announces results from Evrysdi (risdiplam) study in infants with Type 1 spinal muscular atrophy (SMA) published in New England Journal of Medicine (GlobeNewswire)
12.02.21	New phase III data show Roche’s faricimab is the first investigational injectable eye medicine to extend time between treatments up to four months in two leading causes of vision loss, potentially red (GlobeNewswire)
08.02.21	FDA grants Breakthrough Device Designation for Roche's Elecsys Growth Differentiation Factor-15 (GDF-15) assay to help identify patients suitable for innovative treatment addressing unintentional weig (GlobeNewswire)
04.02.21	Roche reports solid results in 2020 (GlobeNewswire)
04.02.21	Roche mit solidem Jahresergebnis für 2020 (GlobeNewswire)
01.02.21	Roche announces the upcoming launch of the SARS-CoV-2 Rapid Antigen Test Nasal allowing for patient self-collection (GlobeNewswire)
25.01.21	Roche renews partnership with Sysmex to deliver haematology testing solutions (GlobeNewswire)
25.01.21	Roche’s faricimab meets primary endpoint in two global phase III studies and shows potential to extend time between treatments up to 16 weeks for people with neovascular age-related macular degenerati (GlobeNewswire)
18.01.21	Roche Annual General Meeting 2021: Exercising of shareholder rights via the independent proxy (GlobeNewswire)
18.01.21	Ordentliche Roche Generalversammlung 2021: Abstimmungen und Wahlen durch die unabhängige Stimmrechtsvertreterin (GlobeNewswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	296.10	1.13 %	K V
Logitech Intl	73.30	0.38 %	K V
Lonza Grp	530.20	0.38 %	K V
Givaudan	3’918.00	0.28 %	K V
ABB	48.85	0.25 %	K V
Nestle	73.58	-0.84 %	K V
Geberit	512.00	-0.89 %	K V
Holcim	86.14	-0.97 %	K V
Zurich Insur Gr	532.40	-1.08 %	K V
Sika	213.00	-2.56 %	K V

mehr

15:58		Zurückhaltung in Europa: Euro STOXX 50 präsentiert sich schwächer
15:58		Börse Frankfurt: So steht der LUS-DAX am Nachmittag
15:58		Börse Frankfurt: DAX präsentiert sich nachmittags leichter
15:58		Anleger in London halten sich zurück: So bewegt sich der FTSE 100 aktuell
15:58		SPI-Handel aktuell: SPI verliert
15:58		Handel in Zürich: SMI verbucht Verluste
13:22		GSK-Aktie verliert: GSK erreicht Fortschritte bei Eierstockkrebs-Therapie
13:13		Wechsel bei Sanofi: Ex-Morphosys-Chef Kress tritt in den Verwaltungsrat ein -Sanofi-Aktie tiefer